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their index cath (MI Group) or as being event-free at three
months (No MI Group). Outcomes through four years were
assessed in landmark analyses using Cox proportional hazards
techniques. RESULTS: Patients in the MI vs. No MI Groups had
a median of 4.2 years follow-up and were similar in age (62 vs.
63 years, p = .44), female sex (35% vs. 33%, p = .35), history of
hypertension (69% vs. 68%, p = .77), history of diabetes (35%
vs. 30%, p = .08), and in multi-vessel CAD (61% vs. 58%,
p = .17). At four years follow-up, patients in the MI vs. No MI
Groups had higher unadjusted rates of death (25% vs. 17%,
p < .001) and death or MI (34% vs. 21%, p < .001). After
adjustment, the hazards of death for patients in the MI vs.
No-MI Groups (HR 1.62; 95% CI 1.30, 2.02; p < .001) and
death or MI (HR 1.84; 95% CI 1.51, 2.24, p < .001) remained
signiﬁcant. When we extended the landmark period from three to
six months after the index cath, the adjusted hazards of death
(HR 1.61; 95% CI 1.34, 1.93; p < .001) and death or MI (HR
1.86; 95% CI 1.58, 2.19; p < .001) were still signiﬁcant. CON-
CLUSIONS: Non-fatal myocardial infarctions signiﬁcantly
increase subsequent rates of death and death or MI in CAD
patients. These ﬁndings suggest a long-term clinical beneﬁt for
therapies that avert non-fatal MIs.
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OBJECTIVES: To assess AF-QoL questionnaire performance in
patients with Atrial Fibrillation (AF) in a usual clinical practice
setting. METHODS: Observational, prospective, multicenter
studywas carried out in 29 Spanish centres. AF diagnosed patients
aged 18 who have changed a clinical and/or therapeutic inter-
vention or were stable according to clinical criteria, and patients
with post heart attack cardiopathy (control group) were enrolled.
All patients went through a baseline visit; only AF patients
underwent a follow up visit (at 3  1 months and 1 month for
unstable and stable patients respectively). At each visit, socio-
demographical and clinical information was gathered; AF-QoL,
SF-36 questionnaires and perception of general health status were
administered. AF-QoL is an 18-item questionnaire with 3
domains: psychological, physical and sexual. Questions refer to
previous month. Answers are 5 levels Likert-like. AF-QoL scores
range between 0–100,where 0 is poorHRQoL.RESULTS:A total
of 417 patients were included: 341 AF patients and 76 control
patients. Mean (SD) age was 61.2(12.4) and 31.4% were women.
AF type distribution was: 37.5% paroxysmal, 42.9% persistent
and 19.6% permanent. AF-QoL was completed by 88.5% of
patients. AF-QoL mean overall global score in AF patients was
43.6 and 51.7 in control group (p < 0.05). AF-QoL showed good
internal consistency (0.92) and good test-retest reliability (0.86) in
stable AF patients. Patients with more symptoms and worse
NYHA functional class at baseline and at the end of follow-up
visit showed lower scores in AF-QoL. AF-QoL correlations with
SF-36 and overall perception of general health status question
were moderate-high (0.32–0.69) and moderate (0.49) (p < 0.01)
repectively. AF-QoL effect size scores in patients declaring health
status positive changes was 1.06, 0.2 for those with no changes
and 0.1 for patients with negative changes. CONCLUSIONS:
AF-Qol has shown to be feasible, valid, reliable and responsive to
clinical changes in the context of clinical practice.
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OBJECTIVES: To predict the percentage of patients achieving
multiple optimal lipid values (OLV) after one year of combina-
tion fenoﬁbric acid (FA) + statin therapy or statin monotherapy.
METHODS: A dyslipidemia outcomes model was used to predict
multiple OLV attainment (any 3 of 4 targets: total-C, LDL-C,
HDL-C, or TG) among a cohort of 1000 patients with multiple
lipid abnormalities (MLA). Optimal lipid levels for HDL-C
(value >40 mg/dL for men, >50 mg/dL for women), LDL-C
(value <130 mg/dL), TG (value <150 mg/dL), and total-C (value
<210 mg/dL) were based on U.S. clinical practice guidelines.
Baseline lipid values were simulated with National Health and
Nutrition Examination Survey data, used to determine the shape
of lipid distributions (gamma for TG and log normal for the
others) and the correlation between these parameters. Mean
initial and on-treatment lipid values were obtained from three
12-week FA/statin studies, where FA 135 mg co-administered
with atorvastatin, rosuvastatin, and simvastatin at low (20 mg,
10 mg, 20 mg, respectively) and moderate doses (40 mg, 20 mg,
40 mg, respectively) was compared to FA and corresponding
statin monotherapy doses. RESULTS: Compared to equivalent
statin monotherapy, the addition of FA 135 mg to low-dose
simvastatin, rosuvastatin, and atorvastatin was predicted to
result in 43% (678 vs. 473 per 1000), 31% (814 vs. 621 per
1000), and 43% (723 vs. 506 per 1\000) more patients simulta-
neously achieving multiple OLV. The number of patients pre-
dicted to achieve multiple OLV increased by 16%, 18% and 25%
with FA + moderate-dose simvastatin, rosuvastatin, and atorvas-
tatin over equivalent dose statin monotherapy, respectively.
CONCLUSIONS: Patients with MLA receiving statin mono-
therapy may require add-on treatment to achieve multiple lipid
targets. This analysis suggests that treatment with FA in combi-
nation with low- and moderate-dose statin therapy may enable
more patients to simultaneously achieve OLV compared to statin
monotherapy.
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OBJECTIVES: To assess the cost-effectiveness of ivabradine in
stable angina patients in the Dutch health care setting in 2007.
METHODS: A Markov model was developed to estimate the
cost-effectiveness of ivabradine. The analysis was performed for
stable angina patients, who currently are candidate for revascu-
larisation. Data sources used included 1) Ivabradine clinical trial
data, 2) Data of the Dutch Heart Foundation, and 3) Data of the
Euro Heart Survey (European Cardiology database). Further-
more, published literature, ofﬁcial Dutch price/tariff lists and
national population statistics are used. The time horizon of the
model was 5 years in order to capture the long-term economic
impact of ivabradine. RESULTS: The results show that the use of
ivabradine leads to additional drug costs of €3873 over a period
of 5 years, which are offset by a cost saving of €8699 due to fewer
revascularisations (€1210 in the ivabradine arm versus €9909 in
the revascularisation arm) over a period of 5 years. As a result the
A342 Abstracts
use of ivabradine leads to a total cost saving of €4826 per patient
over 5 years. The use of ivabradine also leads to a higher effec-
tiveness, as it reduces the average number of revascularisation
procedures from 1.100 to 0.143, including the initial revasculari-
sation procedures for the standard care arm of the model. The
number of revascularisations during the 5-year period is about
similar, when excluding the initial revascularisation procedure
(0.100 to 0.143). Sensitivity analyses show that ivabradine
remains cost saving over the complete range of the input vari-
ables. CONCLUSIONS: Ivabradine is a cost-effective treatment
and, in fact, a dominant treatment: Ivabradine yields to a higher
effectiveness as standard treatment with respect to number of
revascularisations, but leads to substantial overall cost savings.
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OBJECTIVES: To estimate the cost-effectiveness of atorvastatin
10 mg compared with no treatment for the primary prevention of
cardiovascular (CV) events in Type 2 diabetes patients with no CV
history. METHODS: A Markov model with 1-year cycles was
developed to simulate theCV event and death risk according to the
therapeutic approach initiated. The transition probabilities for
CV event in the ‘no statin treatment’ group were derived from the
risk-equations reported from the large UK Prospective Diabetes
Study (UKPDS). The hazard ratio (HR) from the CARDS clinical
trial (0.63; 95% conﬁdence interval [CI], 0.48, 0.83; P = 0.001)
was used to adjust these CV event probabilities in the atorvastatin
10 mg treatment group. Characteristics of Type 2 diabetes
patients with no CV history were derived from the Belgian Opti-
mize Cardiovascular Prevention in Diabetes (OCAPI) survey. The
public health care payers’ perspective was taken into account for
costing. The direct medical costs of CV events were based on the
Public Health Authorities’ hospital database for acute care costs
and on literature for follow up costs. Drug cost did consider the
impact of generic entry on the reimbursement system. Costs were
valued at year 2008; costs and outcomes were respectively dis-
counted at 3 and 1.5%. RESULTS: Based on a 5-year time
horizon, atorvastatin was demonstrated to be cost-effective with
an incremental cost/QALYof €23,426.Over a lifetime horizon (25
years), atorvastatin was a cost-neutral therapeutic approach (€9/
QALY). At a threshold of €30,000/QALY, atorvastatin had a
99.3% probability to be cost-effective. Furthermore, for higher
risk diabetic patients managed in specialist hospital diabetes
centres, atorvastatin was cost-saving. CONCLUSIONS: Com-
pared to no treatment, the use of atorvastatin 10 mg as a primary
prevention strategy in Type 2 diabetes patients not only appears to
be cost-neutral over a lifetime, but improves CV outcomes.
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OBJECTIVES: Following broadening of the EMEA license for
advanced follicular lymphoma (FL) which now allows ﬁrst line
treatment with rituximab added to chemotherapy without
restriction to the regimen, we evaluated the cost-effectiveness of
rituximab added to commonly used chemotherapy regimens
from the perspective of the UK national health care system.
METHODS: A Markov model was developed using published
results from 4 phase III randomized-controlled clinical trials
evaluating progression-free survival (PFS) and overall survival
(OS) in patients with advanced FL. These trials compared the
addition of rituximab to chemotherapy regimens of either MCP,
CVP, CHOP or CHVP versus chemotherapy alone. Rates of
disease progression were derived from the PFS Kaplan-Meier
curves using parametric curve ﬁtting, mortality rates were
obtained from the Scotland-Newcastle Lymphoma Group data-
base and UK age-speciﬁc mortality tables. FL patient utilities
elicited using the EQ-5D were applied to PFS and progressed
health states. The duration of the treatment effect of rituximab
was applied for the period of follow-up speciﬁed in each of the
clinical trial publications. Medication, supportive care costs and
quality-adjusted life years (QALYs) were estimated over a life-
time time horizon (25 years) and discounted at 3.5% per annum.
Univariate and probabilistic sensitivity analysis was performed to
evaluate uncertainty. RESULTS: The addition of rituximab to
chemotherapy increased QALYs by 1.223, 1.034, 0.858 and
0.471 years for MCP, CVP, CHOP and CHVP, respectively, com-
pared to chemotherapy alone. The incremental cost per QALY
gained was £5620, £6455, £7970 and £8422, for MCP, CHOP,
CVP and CHVP, respectively, all below commonly used thresh-
olds in the UK. Sensitivity analyses indicated these results were
robust, and most sensitive to the duration of treatment effect.
CONCLUSIONS: For all chemotherapy regimens evaluated, the
model demonstrated the addition of rituximab increased quality-
adjusted life expectancy and is a highly cost-effective treatment
option for patients with advanced FL.
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OBJECTIVES: The impact of cervical cancer prevention,
through 12-year-old female vaccination with CervarixTM (Glaxo-
SmithKline), has been published for many countries at the
national level. However, to our knowledge no attempt has been
made to address the impact at a regional level. Since the Italian
health reforms of the early 1990s, introducing “managerialism”,
decentralization and quasi-market mechanisms; regional authori-
ties have consequently been experimenting with different orga-
nizational and funding models to achieve an acceptable
combination of equity, efﬁciency, freedom of choice and cost-
containment. METHODS: A Markov model, previously des-
cribed and successfully adapted to the national scenario (La
Torre, 2007), has been used to explore the impact of prophylactic
cervical cancer vaccination with CervarixTM at a regional level in
Italy. Resource use was based on a standard therapeutic path
applied to all regions. However we quantiﬁed the impact of the
so-called “decentralization progress” by collecting regional data
on: Pap-test coverage, tariffs for treatments and cost of the vac-
cination course. The analyses were combined with regional
budget impact analyses, considering the demography and the
effective tender price for each region. RESULTS: Our analyses
demonstrated the heterogeneity present at regional level in Italy
(e.g. regular screening, ranges from 36% to 84%; cost of cervical
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